Project Grant P30GM149398
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,387 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2025 through April 30, 2029, funds research investigating lung vascular Group 3 Innate Lymphoid Cell (ILC3) subpopulations and their roles in antibacterial immunity and vascular regeneration. The...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $2.25 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 1, 2025, with a completion date of March 31, 2030. The grant funds research to reconceptualize disease progression in pulmonary fibrosis (PF), a progressive, fatal lung disease for which current FDA-approved treatments provide modest benefits while...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $491,056.01 to The Research Foundation For The State University Of New York (SUNY at Binghamton) on May 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Vascular Smooth Muscle VPS34 in Pulmonary Arterial Hypertension," will be completed by April 30, 2028, and is conducted at the Binghamton, New York facility. The grant funds research aimed at...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $812,189.00 to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, to conduct research on the use of clinical CT imaging for screening and subtyping of pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD). The research aims to better understand changes in the pulmonary vasculature and their...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $319,248 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of July 31, 2030. The grant funds research investigating hypoxia-inducible factor (HIF)-driven modulation of alveolar regeneration to address idiopathic pulmonary fibrosis (IPF). The research deliverables include...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $248,999 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2028. This award supports research investigating the mechanotransduction regulation of cellular metabolism in idiopathic pulmonary fibrosis (IPF), a progressive scarring disease with limited therapeutic options. The research...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports comprehensive research investigating the mechanisms by which pulmonary influenza A virus (IAV) infection promotes cardiovascular disease. The research, led by Dr. Jeffrey Downey at the Icahn School of Medicine at Mount Sinai in New York, employs innovative mouse models to examine how IAV translocates from the lung to the heart and...
- Federal Project Grant Summary Rhode Island Hospital received a $651,380 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of May 31, 2029. The grant funds research on coronary vascular resilience through modulation of mitochondrial reactive oxygen species (ROS) in endothelial cells. The primary deliverable is an investigation into molecular mechanisms...
- Federal Project Grant Award Summary Vanderbilt University Medical Center (VUMC) received a $874,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for August 31, 2026. The grant funds a prospective clinical trial evaluating personalized oxygen therapy targets for mechanically ventilated critically ill adults. Building on prior randomized controlled...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $1,151,498 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective March 1, 2026 through January 31, 2033, supports fundamental research aimed at understanding lung epithelial development and regeneration to address end-stage lung diseases, particularly idiopathic...
CARDIOPULMONARY VASCULAR BIOLOGY COBRE - THE VISION OF THE CARDIOPULMONARY VASCULAR BIOLOGY (CPVB) COBRE PROGRAM IS TO DEVELOP EFFECTIVE APPROACHES TO PREVENT AND TREAT VASCULAR DISEASES AFFECTING THE PULMONARY AND CARDIOVASCULAR SYSTEMS THROUGH BETTER UNDERSTANDING OF DISEASE MECHANISMS. THIS WILL BE ACCOMPLISHED BY SERVING AS AN INTERDISCIPLINARY CENTER WHICH PROMOTES COLLABORATIVE RESEARCH AND PROVIDES EXCELLENT TECHNICAL SUPPORT AND RESOURCES TO INVESTIGATORS. THE OVERALL MISSION OF THE CPVB COBRE PROGRAM HAS BEEN TO BUILD THE HUMAN AND TECHNICAL INFRASTRUCTURE AND SERVICES THAT SERVE AS CATALYSTS TO INCREASE CPVB RESEARCH IN THE STATE. CARDIOVASCULAR AND PULMONARY DISEASES ARE AMONG THE LEADING CAUSES OF MORBIDITY AND MORTALITY IN THE US AND IN THE WORLD. CORONARY ARTERY DISEASE (CAD) IS THE LEADING CAUSE OF MORBIDITY AND MORTALITY. RESPIRATORY DISEASES ARE THE 3RD AND 4TH LEADING CAUSES OF DEATH AND ARE FREQUENTLY COMPLICATED BY PULMONARY VASCULOPATHY AND CARDIOVASCULAR CO-MORBIDITIES THAT MARKEDLY WORSEN PROGNOSIS. WE HAVE LEARNED THAT INFECTION WITH SARS-COV-2 VIRUS DAMAGES MULTIPLE ORGANS, WITH CARDIOVASCULAR, RESPIRATORY, AND VASCULAR COMPLICATIONS. THUS, THERE IS AN IMPORTANT NEED TO UNDERSTAND THE PATHOGENESIS OF CARDIOPULMONARY VASCULAR DISEASES IN ORDER TO DEVELOP MORE EFFECTIVE TREATMENTS AND PREVENTION. THE OVERALL GOAL OF THE CPVB COBRE PROGRAM IS TO FACILITATE HIGH IMPACT VASCULAR BIOLOGY RESEARCH. THE CPVB COBRE PROGRAM PROVIDES INFRASTRUCTURE WITH ADMINISTRATIVE, PILOT PROJECT, AND TWO TECHNICAL CORES, THUS PROVIDING OPPORTUNITIES TO EXPAND AREAS OF INVESTIGATION, EXPERIMENTAL AND TECHNICAL APPROACHES, AND SCIENTIFIC COLLABORATIONS. THE SPECIFIC AIMS OF PHASE III CPVB COBRE ARE TO: I) AWARD HIGH-IMPACT RESEARCH PROJECTS IN THE AREA OF CARDIOPULMONARY VASCULAR BIOLOGY; II) PROVIDE EFFECTIVE AND HIGH-QUALITY SERVICES IN CELL ISOLATION AND EX VIVO ORGAN FUNCTION (CIOF), MITOCHONDRIAL FUNCTION, AND IN VIVO IMAGING (MF-II); III) COLLABORATE WITH IDEA PROGRAMS IN RHODE ISLAND (RI) AND OTHER STATES TO FOSTER SCIENTIFIC NETWORKS BY PROVIDING PROGRAMMING, FUNDING, TECHNICAL SERVICES, AND RESOURCES TO ENHANCE RESEARCH PRODUCTIVITY; AND IV) MAINTAIN A ROBUST LINE OF INVESTIGATION IN VASCULAR BIOLOGY THAT MEETS THE NEEDS OF THE SCIENTIFIC COMMUNITY AND FURTHERS RESEARCH IN PREVENTION AND TREATMENT OF CARDIOPULMONARY VASCULAR DISEASES. CONTINUATION OF THE CPVB COBRE INTO PHASE III WILL SUSTAIN THE ADMINISTRATIVE STRUCTURE FOR SEMINARS AND WORKSHOP PLANNING, ENGAGEMENT, AND PROFESSIONAL DEVELOPMENT SUPPORT OF INVESTIGATORS, AND EXPERTISE IN CELL ISOLATION AND EX VIVO ORGAN FUNCTION, MITOCHONDRIAL FUNCTION, AND IN VIVO IMAGING. WE WILL EXPAND AND ENRICH THE VASCULAR BIOLOGY RESEARCH COMMUNITY BY PROMOTING NEW COLLABORATIONS AND ENGAGING SCIENTISTS NEW TO THE FIELD FROM A VARIETY OF DISCIPLINES. AT THE END OF PHASE III, WE EXPECT TO TRANSITION TO A SUSTAINABLE CPVB CENTER SERVING AS A HOME TO THE CVPB RESEARCH COMMUNITY WITH HIGH QUALITY CORE SERVICES, SIGNIFICANT INSTITUTIONAL SUPPORT, AND COMMITMENT TO CONTINUE THE DEVELOPMENT OF EFFECTIVE APPROACHES TO COMBAT OR RESOLVE CARDIOPULMONARY VASCULAR DISEASES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $884.9k | 8/7/25 | ||
| Not listed | $0 | 1/20/25 | ||
| Not listed | $0 | 1/20/25 | ||
| Not listed | $898.4k | 5/17/24 | ||
| Not listed | $898.4k | 5/17/24 |